Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients.
2014
Objectives:TMC310911 is a novel HIV type-1 (HIV-1) protease inhibitor with broad in vitro antiviral activity. In this phase 2a, open-label randomized study, the antiviral activity, pharmacokinetics, and safety and tolerability of ritonavir-boosted TMC310911 was assessed.Methods:In this study, treatm
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
15
References
12
Citations
NaN
KQI